Infectious Diseases Now is a premier academic journal dedicated to the evolving field of infectious diseases, published by Elsevier France - Éditions Scientifiques Médicales Elsevier. With an ISSN of 2666-9927 and an E-ISSN of 2666-9919, this journal stands at the forefront of disseminating critical research and clinical insights from 2021 to 2024. The journal's commitment to open access means that groundbreaking studies are readily available to researchers, healthcare professionals, and students, fostering a collaborative approach to tackling global health challenges. As evidenced by its Q2 quartile ranking in the 2023 Scopus category of Infectious Diseases, and its impressive position within the top 25% of its field, Infectious Diseases Now serves as an essential resource for those involved in the study and management of infectious diseases. By publishing high-quality research, case studies, and reviews, the journal plays a pivotal role in advancing knowledge and improving patient care in this vital area of medicine.

Gut Pathogens, published by BMC in the United Kingdom, is a premier open-access journal focusing on the intersection of gut health and infectious diseases. With its impact firmly established since its inception in 2009, the journal has earned impressive rankings, including Q1 in renowned categories such as Gastroenterology, Infectious Diseases, Microbiology, and Parasitology, while maintaining a strong presence in Virology. The journal serves as a vital resource for researchers, professionals, and students interested in the intricate relationships between gut microbiota and pathogenic organisms, offering insights that drive advancements in treatment and prevention strategies. By providing unrestricted access to high-quality research, Gut Pathogens fosters a collaborative environment, encouraging the dissemination of knowledge and innovation within the field. The journal publishes original research, reviews, and case studies, all designed to address contemporary challenges in gut health, ultimately aiming to improve patient outcomes and public health worldwide.

The Canadian Journal of Infectious Diseases & Medical Microbiology, published by HINDAWI LTD, is a pioneering open-access journal focused on advancing the fields of infectious diseases and medical microbiology, with its commitment to disseminating innovative research since 2004. With the ISSN 1712-9532 and E-ISSN 1918-1493, the journal is recognized for its high-caliber contributions, achieving a 2023 Q2 ranking in Infectious Diseases and a Q3 ranking in Medical Microbiology, as per the prestigious Scopus rankings. Offering a global platform for researchers and clinicians, the journal is crucial for fostering collaboration and sharing knowledge across borders, emphasizing its role as a significant resource for addressing pressing health challenges. With an HIndex that indicates an increasing influence in the scientific community, the journal maintains its focus on impactful studies that inform clinical practices and policies, while also being available to a diverse audience through its open-access format. Based in Egypt, the journal looks forward to continuing its impact up to 2024 and beyond, serving as a vital forum for scientific exchange and practical applications in the fight against infectious diseases.

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

EPIDEMIOLOGY AND INFECTION is a premier open-access journal published by Cambridge University Press, dedicated to advancing the field of epidemiology and infectious diseases. With an ISSN of 0950-2688 and E-ISSN of 1469-4409, this journal has been at the forefront of disseminating impactful research since its inception in 1970. As of 2023, it holds a prestigious Q2 ranking in both the fields of Epidemiology and Infectious Diseases, reflecting its significant contribution to these critical areas of study, with Scopus rankings placing it at #70 in Epidemiology and #163 in Infectious Diseases. The journal aims to publish high-quality, peer-reviewed studies that contribute to our understanding and management of infectious diseases globally. Operating under an open-access model since 2020, EPIDEMIOLOGY AND INFECTION ensures that research is accessible to a wide audience, fostering collaboration and innovation among researchers, professionals, and students alike. With a commitment to excellence, this journal is an essential resource for those looking to stay abreast of the latest developments in epidemiological research and infectious disease management.

Therapeutic Advances in Infectious Disease is a distinguished journal published by SAGE Publications Ltd, dedicated to advancing knowledge in the vital field of infectious diseases and pharmacology. With an impactful Open Access model since 2019, the journal facilitates unrestricted access to a wealth of high-quality research, enabling researchers, clinicians, and educators to stay at the forefront of infectious disease management and treatment. As a recognition of its contribution to the scientific community, the journal holds a prestigious Q1 quartile ranking in both Infectious Diseases and Medical Pharmacology as of 2023, underscoring its influence and relevance in these domains. The journal is positioned favorably within the Scopus rankings, with an impressive standing in the diverse categories of Medicine, emphasizing its commitment to disseminating innovative research. Through a rigorous peer-review process and a broad scope that covers therapeutic advancements, Therapeutic Advances in Infectious Disease serves as an essential resource for anyone involved in combating infectious diseases, offering insights that drive clinical applications and enhance patient care.

Mediterranean Journal of Infection Microbes and Antimicrobials is a distinguished open-access journal published by GALENOS PUBL HOUSE, dedicated to advancing the understanding of infectious diseases and microbiology. Since its inception in 2011, this journal has been a vital resource for researchers, professionals, and students interested in the intricate world of microbes and their impacts on human health. With its ISSN 2147-673X, the journal has progressively gained visibility, although it currently holds a Q4 ranking in multiple categories including Immunology and Microbiology, and Infectious Diseases for the year 2023. The journal operates from its headquarters in Istanbul, Turkey, and features a rich array of articles that contribute to the field’s body of knowledge. As a platform enhancing the accessibility of research, it invites submissions from global contributors to foster collaboration and innovation in tackling microbial challenges.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, published by ELSEVIER SCI LTD, stands as a leading platform in the realm of infectious diseases, contributing significantly to the global understanding of this critical field. With an impressive impact factor, the journal maintains a distinguished Q1 ranking across various categories, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, demonstrating its high relevance and influence among contemporary research. Since its inception in 1996, it has embraced an Open Access model, allowing for wider dissemination of essential research findings that can inform public health policies and clinical practices. With a commitment to advancing scientific knowledge, this journal is not only a vital resource for researchers and professionals but also serves as an invaluable educational tool for students interested in the complexities of infectious diseases and their management. For those looking to stay at the forefront of research and innovation in this field, the INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES is an indispensable resource.

Diseases is a premier Open Access journal dedicated to the dissemination of cutting-edge research in the field of medicine, particularly focusing on the multifaceted challenges posed by various diseases. Published by MDPI in Switzerland since 2013, this journal provides a platform for innovative studies and comprehensive reviews that address the latest developments in disease prevention, diagnosis, and treatment. With an E-ISSN of 2079-9721, it holds a respectable rank of #394 out of 636 in the General Medicine category according to Scopus, indicating a growing impact within the community, marked by its 38th percentile ranking. The journal, covering converged years from 2020 to 2024, aims to foster interdisciplinary collaboration and knowledge sharing among researchers, healthcare professionals, and students, ultimately contributing to the enhancement of global health outcomes. Accessible without charge, Diseases exemplifies a commitment to advancing research and practices aimed at improving human health on a global scale.

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.